12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Public ClinicalTrials.gov record NCT02303626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Study identification
- NCT ID
- NCT02303626
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- BCX4161 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2014
- Primary completion
- Dec 31, 2015
- Completion
- Dec 31, 2015
- Last update posted
- Nov 16, 2025
2014 – 2016
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35209 | — |
| Not listed | Scottsdale | Arizona | 85251 | — |
| Not listed | Granada Hills | California | 91344 | — |
| Not listed | San Diego | California | 92093 | — |
| Not listed | San Diego | California | 92112 | — |
| Not listed | Walnut Creek | California | 94598 | — |
| Not listed | Colorado Springs | Colorado | 80907 | — |
| Not listed | Shreveport | Louisiana | 71106 | — |
| Not listed | Chevy Chase | Maryland | 20815 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Plymouth | Minnesota | 55446 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | Charlotte | North Carolina | 28277 | — |
| Not listed | Cincinnati | Ohio | 45267 | — |
| Not listed | Oklahoma City | Oklahoma | 73131 | — |
| Not listed | Tulsa | Oklahoma | 74133 | — |
| Not listed | Lake Oswego | Oregon | 97035 | — |
| Not listed | Hershey | Pennsylvania | 17033 | — |
| Not listed | Pittsburgh | Pennsylvania | 15241 | — |
| Not listed | Dallas | Texas | 75231 | — |
| Not listed | Galveston | Texas | 77555 | — |
| Not listed | Fairfax | Virginia | 63141 | — |
| Not listed | Spokane | Washington | 99204 | — |
| Not listed | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02303626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02303626 live on ClinicalTrials.gov.